Molecular diagnostics (MDx) is used to assess an individual's health at the molecular level, analyzing specific genetic sequences encoded in deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or the proteins that are expressed from these genetic sequences. All disease is a result of genes interacting with the environment. MDx provide a golden path toward personalized health care, precision medicine and predictive health care.
Molecular diagnostics is the fastest growing segment of the broader diagnostics market. The market for MDx is expected to grow from $8.5 billion at present to around $20 billion by 2030. The growth of MDx is driven by the technology developments, the growth of the point-of-care MDx market, and the continued discovery of genetic biomarkers with proven clinical utility.
There are multiple techniques for testing genetic materials, some of which lend themselves more readily to miniaturization. Initially, molecular diagnostics were carried out using hybridization methods, such as fluorescence in situ hybridization. Later, polymerase chain reaction (PCR) and microarrays offered high throughput and more accurate tests. More recently DNA sequencing is an alternative for MDx as an unbiased and direct method. This report gives a comprehensive study and complete analysis of the important trends in the field of molecular diagnostics and particularly focuses on three categories of technologies and equipment:
• Microarrays:
• Polymerase chain reaction (PCR)
• DNA sequencing
For each technology category, this report summarises the technology advancements and innovations, lists the dominant companies and their key technologies, and provides ten-year forecasts on the market growth from 2020-2030. The forecasts are mainly built on information derived from historic data of key players, intensive company interviews, and the assumptions of the adoption rate of new technologies such as digital polymerase chain reaction and third generation sequencing.
Traditionally, molecular diagnostics has been used in life science research, infectious disease testing and cancer diagnostics, but the market of MDx is expanding into new areas, such as companion diagnostics, liquid biopsy, direct-to-consumer and more. The report gives a 10-year market forecast segmented by the following applications:
• Infectious disease
• Cancer and liquid biopsy
• Genetic testing
• Life science research
• Companion diagnostic
• Direct-to-consumer
This report provides 30 company profiles of the main players across different segments. It also gives a comprehensive study on both currently available and incoming devices. This report will be useful to any company wishing to know the molecular diagnostics market, advanced techniques and devices, current market size and future tendency.
MolecularUS$ 5,995